Chinese cancer treatment company aims for US listing

Concord Medical Services aims to raise up to $138 million from an IPO and is expected to start trading on the NYSE late next week.

Concord Medical Services, the operator of China's largest network of cancer treatment centres, has started to accept orders for an initial public offering that aims to raise between $114 million and $138 million. The Beijing-based company is expected to start trading on the New York Stock Exchange towards the end of next week.

Concord will provide an opportunity for international investors to get exposure to a Chinese healthcare company that operates at the patient level. So far, investors have been...

To continue reading, please login or register for free

Click for more on: ipo | nyse | healthcare | cancer | radiotherapy | cicc | jp morgan. | morgan stanley

Print Edition

FinanceAsia Print Edition